Tamoxifen kills breast cancer cells not only by binding to estrogen receptors but also by blocking glutamine uptake, reducing glutathione production.5 Given the impact of SIRT4 on glutamine metabolism, we hypothesized that SIRT4 may affect the sensitivity of ER‐positive breast cancer to tamoxifen. This evidence concerns the gene ESR1 and breast carcinoma.